Effects of topical nipradilol on early diabetic retinopathy in SDT rats

Open Diabetes Journal

Volumn 4, Issue SPEC. ISSUE 1, 2011, Pages 114-118

  Kinoshita, Nozomi ^a   Kakehashi, Akihiro ^a   Dobashi, Yoh ^a   Ono, Ryuichiro ^a   Toyoda, Fumihiko ^a   Kambara, Chiho ^a   Yamagami, Hiroko ^a   Kitazume, Yusuke ^b   Kobayashi, Eiji ^a   Osakabe, Yasuhiro ^c   Kudo, Motoshige ^c   Kawakami, Masanobu ^a   Kanazawa, Yasunori ^d  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Medical Affairs Department   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d Japan Diabetes Foundation   (Japan)

Author keywords

and blocker; Diabetic retinopathy; Electron microscopy; Nipradilol; Nitric oxide (NO) donor; SDT rat

Indexed keywords

GLUCOSE; LIPOFUSCIN; NIPRADILOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VOLUME; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG STRUCTURE; ENDOTHELIUM CELL; GLUCOSE BLOOD LEVEL; MALE; MICROVILLUS; MITOCHONDRION; NONHUMAN; PINOCYTOSIS; PRIORITY JOURNAL; RAT; RIBOSOME;

EID: 80455157982     PISSN: None     EISSN: 18765246     Source Type: Journal    
DOI: 10.2174/1876524601104010114     Document Type: Article

References (21)

1. Kakehashi A, Saito Y, Mori K, et al. Characteristics of diabetic retinopathy in SDT rats. Diabetes Metab Res Rev 2006; 22: 455-61.
2. Kakehashi A. Pathogenesis of diabetic retinopathy: Lessons from diabetic animal model. Endocrinol Diabetol 2003; 17:31-7 (Japanese).
3. Abiko T, Abiko A, Clermont AC, et al. Characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes: role of oxidants and protein kinase-C activation. Diabetes 2003; 52: 829-37.
4. Kinoshita N, Kakehashi A, Inoda S, et al. Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. Diabetologia 2002; 45: 735-9.
5. Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 1998; 39: 2190-4.
6. Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 1999; 96: 10836-41.
7. Ono R, Kakehashi A, Ito Y, et al. Effect of topical nipradilol on retinal microvascular leukocyte adhesion in diabetic rats. Ophthalmic Res 2006; 38: 270-3.
8. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994 15; 118:445-50.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
10. Tanaka Y, Katoh S, Hori S, Miura M, Yamashita H. Vascular endothelial growth factor in diabetic retinopathy. Lancet 1997; 349(9064): 1520.
11. Qaum T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42: 2408-13.
12. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139: 81-100.
13. Wright WS, Harris NR. Ozagrel attenuates early streptozotocin-induced constriction of arterioles in the mouse retina. Exp Eye Res 2008; 86: 528-36.
14. Dorner GT, Garhofer G, Kiss B, et al. Nitric oxide regulates retinal vascular tone in humans. Am J Physiol Heart Circ Physiol 2003; 285: H631-H636.
15. Kato N, Yashima S, Suzuki T, Nakayama Y, Jomori T. Long-term treatment with fidarestat suppresses the development of diabetic retinopathy in STZ-induced diabetic rats. J Diabetes Complications 2003; 17: 374-9.
16. Song E, Dong Y, Han LN, et al. Diabetic retinopathy: VEGF, bFGF and retinal vascular pathology. Chin Med J (Engl) 2004; 117: 247-51.
17. Li Q, Verma A, Han PY, et al. Diabetic eNOS knockout mice develop accelerated retinopathy. Invest Ophthalmol Vis Sci 2010; 51: 5240-6.
18. Bek T. Epidemiology of Diabetic Retinopathy. 2nd ed. Van Bijsterveld OP, Ed. London: Martin Dunitz Ltd 2000.
19. Mizuno K, Koide T, Yoshimura M, Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci 2001; 42: 688-94.
20. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci 2000; 41: 961-4.
21. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Deliv Rev 2001; 52: 37-48.